Trial Profile
A MULTICENTER, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF AL002 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs AL-002 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Alector
- 23 Feb 2023 New trial record